$10 Billion Deal, page-9308

Well firstly the processes are slow and precise, so many have fallen by the wayside by rushing their product only to find out it's a dud. Secondly the results on mice were taken against the Delta variant and as results came out Omicron surfaced. So to me it is obvious the company would go back to the mice and see what the 225 does against the newest strain. Having a win on both variants gives the company so much more leverage than others would have. So patience is the game, if you don't have patience you're in the wrong game.